This $3,503,736 Project Grant from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a 2-year R61 phase and 3-year R33 phase to develop and test a multilevel substance use disorder (SUD) and overdose prevention strategy for rural youth involved in the county legal system in Washington state. The R61 phase will co-design the multilevel SUD/overdose prevention intervention and implementation plan with a multisector group. The...
This federal Project Grant award, totaling $346,911, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award, valid from August 15, 2024 to July 31, 2026, will support a cross-species study to identify neurocognitive, genetic, and socioenvironmental risk factors for substance use disorders (SUDs). The key objectives of the project are to: 1) determine how early life environment influences neurocognitive development...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,624,920.00 to support a randomized clinical trial conducted by the Lovelace Biomedical Research Institute. The study aims to demonstrate the reliability and generalizability of improved outcomes in offenders with substance use disorders by matching specific cognitive deficits with targeted skills training interventions. The research will...
The National Institute on Drug Abuse (NIDA), through the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $264,000 Project Grant to Innovation Research And Training, Inc. (IRT), a woman-owned small business research organization based in Durham, North Carolina. The purpose of this 3-year grant, with an award date of September 15, 2024, is to evaluate the "Substance of Change: Building Assets in Mentees Affected by Substance Misuse" (SOC), an interactive, multimedia,...
This $197,748 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to develop and pilot an enhanced low-dose buprenorphine initiation (LDI) program to improve treatment outcomes for individuals with opioid use disorder (OUD), especially those using fentanyl. The key objectives of this 4-year project are to: 1) identify barriers to successful LDI completion through qualitative interviews, 2)...
The National Institute on Drug Abuse (NIDA) awarded a $177,170 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Massachusetts Medical School (UMass Medical) for the "Implementation of Medications for Opioid Use Disorder in Massachusetts Jails" project. The funding will support a mixed-methods study to analyze the implementation of medications for opioid use disorder (MOUD) treatment in Massachusetts county jails. The research aims...
This federal Project Grant award, titled "Establishing an Evidence Base to Increase the Utility of Urine Drug Testing in Opioid Use Disorder Treatment", is funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $2,730,450 award aims to identify variation in real-world use of urine drug testing (UDT) that can be modified by clinical guidelines and policy change, and to examine patient- and clinician-level factors...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop advanced statistical methods for improving the effectiveness and efficiency of clinical trials for treating opioid use disorder. The primary objectives are to: Develop efficient parametric and semiparametric estimators for average treatment effects, conditional average treatment effects, and optimal individualized treatment rules...
The National Institute on Drug Abuse (NIDA) awarded a $390,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Regents of the University of Michigan. The grant, titled "Cultivating Recovery: A Pilot Study of Digital Contingency Management for Co-Occurring Opioid and Alcohol Use Disorder," will fund a mixed-methods randomized pilot trial to test the feasibility and acceptability of a digital contingency management intervention for Medicaid...
The National Institute on Drug Abuse (NIDA) awarded a $2,427,126 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Washington State University. The grant, titled "Strength in Healing: Indigenous Community-Led Strategies to Treat Stimulant Use", aims to rapidly implement culturally responsive interventions for stimulant use disorders among American Indian and Alaska Native (AI/AN) populations, who experience disproportionately high rates of fatal...
This National Institute on Drug Abuse (NIDA) Project Grant award for $1,126,100 aims to refine and pilot the R3 Supervision Strategy in substance use disorder (SUD) treatment programs. The funding, awarded under CFDA 93.279 - Drug Use and Addiction Research Programs, will enable the University of Arkansas for Medical Sciences (UAMS) to partner with SUD providers to modify and refine the evidence-based R3 supervision strategy for SUD settings. UAMS will then conduct two pilot cycles with 8 supervisors and 35 counselors at 5 SUD residential treatment programs to assess the feasibility, acceptability, and impact of the refined R3-SUD strategy on organizational, counselor, and client outcomes. This project will provide critical information to inform the design of a future large-scale study to evaluate the effectiveness of the R3-SUD strategy in a broader sample of SUD programs.